Nurses Return to Work After Approving Agreement
Physicians Unite on Need to Retain Welch Road Medical Offices
Vaccine Program Receives Federal Grant to Study Immune System Response to Viruses
Researchers Encourage Minority Patients to Participate in Cancer Studies
Researchers
Encourage Minority Patients
to Participate in Cancer Studies
When oncologist Harlan Pinto and his colleagues were designing a brochure to encourage African-Americans to participate in cancer research studies, they chose a background of kente cloth - a vividly patterned West African fabric. It conveys a subtle message to an audience that is often suspicious of medicine. "If you are aware of the cloth, the pattern says, 'This is speaking to me,' " explained Pinto, an assistant professor of medicine. "And if you don't recognize the pattern, it's still nice to look at."
Since 1993, Pinto, a faculty member at Stanford's Clinical Cancer Center, has been investigating how to encourage more minorities to take part in cancer research studies. He has put what he learned from focus groups with minority doctors and other research into practice through an outreach program that now includes seven northern and central California hospitals, from Chico to San Luis Obispo. The inviting brochures are just one tool for improving relations with minority doctors and their patients.
Race matters when it comes to cancer. According to data from the National Cancer Institute that cover the years 1990 to 1996, blacks have the highest rate of cancer overall - 443 cases per 100,000 people versus 403 per 100,000 people for whites. The frequencies of individual cancers also vary by race. For instance, blacks have the highest rate of prostate and lung cancer, while whites have a higher rate of breast and bladder cancer and of melanoma.
For cancer death rates, the picture looks much the same: Blacks are 33 percent more likely to die of cancer than whites and twice as likely to die as Hispanics, Asians and American Indians. Moreover, though they have a lower incidence of breast cancer than whites, black women are more likely to die of the disease than are women of any other race.
Genetic differences probably play a small role, Pinto said. Untangling this knot of possible causes requires that greater numbers of minorities be included in studies.
Minorities who participate in a trial can be sure they are getting at least the current standard treatment - and they may be getting the future standard.
The racial imbalance in research has shrunk since the 1970s and 1980s, when most cancer clinical trials enrolled almost exclusively middle-class whites, Pinto said. Surveys show that today most treatment studies have roughly the same fraction of African-Americans as the general population. However, prevention trials still fall well short of a representative racial mix, he said.
Although the National Institutes of Health requires that the studies it funds include representative numbers of women and minorities, researchers often have a hard time gathering enough minority patients. To better understand what deters minorities, Pinto and the Eastern Cooperative Oncology Group - an international organization of oncologists, nurses and other experts involved in cancer research - have convened focus groups for minority doctors. Held at four sites around the country, the focus groups asked the doctors whether they would consider recommending patients for one of four hypothetical treatment trials for breast, colorectal, lung and prostate cancers.
The researchers learned that many patients were suspicious of medical research, fearing that they would be experimented on and that many minority doctors shared the mistrust. Fresh in the minds of many blacks is the infamous Tuskegee experiment, conducted at a hospital in Alabama beginning in the 1930s. Black men with syphilis received no treatment so that doctors could study the course of the disease. However, mistrust and fears of abuse predate Tuskegee, Pinto noted.
Another hurdle is the perception that the large medical centers that conduct most research discriminate against minority patients and doctors. Whether or not this kind of bias exists is beside the point, Pinto said. Since many minority doctors and patients believe that it does, a recruitment program can't succeed without addressing the perception.
These doctors also felt they weren't receiving enough information from the researchers at the large medical centers about what kinds of trials were available.
Overall, Pinto and colleagues concluded that doctors in large medical centers need to work more closely with community physicians and do a better job of educating minority doctors and their patients. They published their findings in the March 1999 issue of the Journal of Clinical Oncology.
Pinto and his colleagues continue to conduct focus groups that promote conversation between doctors from the minority community and those from large research hospitals. Ultimately, they hope their efforts will instill minority patients with a more positive view of medical research. "You want to get rid of biases and fears so they can make an informed, rational decision about whether to join a study," Pinto said.
What he and his colleagues learned applies to all clinical trials, Pinto said, because many of the suspicions that keep minorities away from clinical research are widespread in the population at large. For example, many veterans are wary of government studies because of Cold War radiation experiments that exposed thousands of servicemen to atomic blasts.
